and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing…

The filing discloses an amendment to a compensatory equity plan rather than a change in personnel or management.

Entry into a Material Definitive Agreement. On July 23, 2026, 420 South Congress Avenue, LLC (the “Seller”), a wholly owned subsidiary of PetMed Express, Inc. (the “Company”), entered into a Commercial Contract and Addendum of Additional Terms with Redfearn Capital Acquisitions, LLC (the “Buyer”), pursuant to which the Seller agreed to sell to the Buyer the properties located at 410 and 420 South Congress Avenue, Delray Beach, Florida (collectively, the “Properties”) and agreed to consummate…

Director — Leah A. Solivan: Ms. Solivan decided not to stand for reelection at the Company’s 2026 annual meeting of stockholders.

and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing…

Changes in Registrant’s Certifying Accountant. On December 19, 2025, the Company filed, and RSM completed its interim review of, the Company’s Quarterly Reports on Form 10-Q for the three months ended June 30, 2025, and September 30, 2025. Accordingly, the dismissal of RSM as the Company’s independent registered public accounting firm was effective December 19, 2025. RSM’s audit reports on the Company’s consolidated financial statements as of and for the fiscal years ended March 31, 2025 and…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On December 8, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of PetMed Express, Inc. (the “Company”), following a competitive process to determine the Company’s independent registered public accounting firm for the fiscal year ended March 31, 2026, approved the engagement of Baker Tilly US, LLP (“Baker Tilly”) to serve as the Company’s independent registe…

Entry Into a Material Agreement On November 26, 2025, PetMed Express, Inc., a Florida corporation (the “ Company ”), entered into Amendment No. 1 (the “ Amendment ”) to the Rights Agreement, dated as of December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent (the “ Original Rights Agreement ,” and as amended by the Amendment, the “ Amended Rights Agreement ”). Pursuant to the Amendment, the Final Expirat…

Interim Principal Financial Officer and Chief Accounting Officer — Douglas Krulik: The company increased the annual base salary of Douglas Krulik and entered into a Change of Control and General Severance Agreement with him.

Material Modifications to Rights of Security Holders. The information set forth under

Results of Operations and Financial Condition. On November 13, 2025, PetMed Express, Inc. (the “Company”) issued a press release announcing preliminary estimated revenues for the three- and nine-month periods ended September 30, 2025. These preliminary estimated revenues are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of September 30, 2025, or its results of operations for…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly per…

Director — James LaCamp: Appointment of James LaCamp as a director and Audit Committee Chair, bringing significant financial governance expertise to the company.

and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing…

Material Impairments. On October 1, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of PetMed Express, Inc. (the “Company”), upon the recommendation of the Company’s management, concluded that a $1.2 million non-cash impairment of the Company’s PCRX trade name is required to be recorded in the quarter ended March 31, 2025. The Company acquired certain intangible assets, including the PCRX trade name, in its April 2023 acquisition of the issued and outstanding equit…

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) On October 1, 2025, the Company’s Audit Committee, in consultation with management and RSM US LLP, the Company’s independent registered public accounting firm (“RSM”), concluded that the financial statements for the years ended March 31, 2024 and 2023, as included in the Annual Report on Form 10-K for the year ended March 31, 2024 (the “2024 Annual Report”), along with the unaudit…

Interim Chief Executive Officer and President — Leslie C.G. Campbell: Ms. Campbell was appointed as the Interim Chief Executive Officer and President with a specified initial annual base salary.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 20, 2025, PetMed Express, Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for its fiscal year ended March 31, 2025 (the “ Annual Report ”) and its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “ Quarterly Re…

Chief Executive Officer and President — Sandra Campos: Ms. Campos resigned as CEO, President, and director of the company.

Director, Chair of the Audit Committee, member of the Audit Committee and Compensation and Human Capital Committee — Diana Garvis Purcel: Ms. Purcel resigned from her positions on the Board and its committees.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, PetMed Express, Inc. (the “Company”) determined that it was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K”) by the prescribed due date because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and relat…

Results of Operations and Financial Condition. On June 16, 2025, PetMed Express, Inc. (the “Company”) issued a press release announcing preliminary financial results for the fourth quarter and fiscal year ended March 31, 2025. These preliminary financial results are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of March 31, 2025, or its results of operations for the fourth q…

Director — Dr. Gian Fulgoni: Dr. Gian Fulgoni is retiring from the Board upon his term expiration at the 2025 annual shareholders' meeting, and Peter Batushansky has been appointed as a new director.

and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing…

Entry into a Material Definitive Agreement. The information set forth in